127

Index

Note: Page numbers in italic refer to figures, those in bold refer to tables.

7.1 see NG2 acute mixed phenotype with t(6;9) 52 α (alpha) 39 leukaemia see mixed with t(8;21)(q22;q22.1) 54, γ (gamma) 39 phenotype acute leukaemia 55, 93, 112 δ (delta) 39 acute monoblastic leukaemia, with t(9;11) or other KMT2A ε (epsilon) 39 case 102, 118–119 rearranged 52 κ (kappa) 38 acute monoblastic/monocytic acute promyelocytic leukaemia, λ (lambda) 38 leukaemia 33 with t(15;17)(q24.1;q21.2) μ (mu) 39 acute monocytic leukaemia, 48–52, 54, 93, 112 case 100, 116–118 acute undifferentiated a acute myeloid leukaemia leukaemia (AUL) 62 abbreviations ix–x, 47, 89 (AML) 48 case 108, 123 acute basophilic leukaemia associated with Down’s adult T‐cell leukaemia/ 14, 36, 55 syndrome 28, 55 lymphoma (ATLL) 74, acute lymphoblastic leukaemia with bi‐allelic CEBPA 92, 94, 112, 113 (ALL) 55–62, 90, 111 mutation 55 aggressive NK‐cell see also B‐lineage acute case 98, 115 leukaemia 76, 91, 111 lymphoblastic leukaemia immunophenotyping of 27, 73 (B‐ALL) acute myeloid leukaemia ALK1 see CD246 case 103, 119–120 and blastic plasmacytoid ALK‐negative anaplastic large minimal residual disease dendritic cell cell lymphoma 75 (MRD) 77–78 neoplasm 53–54 ALK‐positive anaplastic large therapy‐related 103, 119–120 with inv(3) 52 cell lymphoma 75 T‐lineage acute lymphoblasticCOPYRIGHTED with inv(16) 12, 52, MATERIAL53 ALL see acute lymphoblastic leukaemia (T‐ALL) minimal residual disease leukaemia 60–62, 103–104, 119–120 (MRD) 78 AML see acute myeloid acute mast cell leukaemia with mutated NPM1 leukaemia 20, 23 92, 111 anaplastic large cell lymphoma acute megakaryoblastic with mutated RUNX1 55 75, 95, 113 leukaemia 15, 23, 25, 29, with myelodysplasia‐related case 105, 120 30, 53–54, 55 changes 55 angioimmunoblastic T‐cell with t(1;22)(p13.3;q13.1); not otherwise specified 55 lymphoma 74 RBM15‐MKL1 54, 93 with t(1;22) 92 annexin A1 39

Immunophenotyping for Haematologists: Principles and Practice, First Edition. Barbara J. Bain and Mike Leach. © 2021 John Wiley & Sons Ltd. Published 2021 by John Wiley & Sons Ltd.

bindex.indd 127 01-09-2020 18:39:03 128 Index

antigen expression during BCL6 39 CD4 13 maturation of the B‐ BCL10 39 CD5 13 lymphocyte lineage in the Bernard–Soulier syndrome CD7 13–14 bone marrow and in 6, 25 CD8 14 peripheral lymphoid blastic plasmacytoid dendritic CD9 14 tissues 51 cell neoplasm 65 CD10 14–15 antigen expression during case 101, 117 CD11a 15 maturation of the 12–13, 17 CD11b 15 erythroid lineage in the B‐lineage acute lymphoblastic CD11c 15 bone marrow 51 leukaemia (B‐ALL) CD13 15–16 antigen expression during 55–60, 90, 111 CD14 16 maturation of the monocyte BCR‐ABL1‐like 56, 57 CD15 16–17 lineage in the bone marrow with high hyperdiploidy 33, CD16 17 and, in tissues, to 55–57 CD19 17 macrophages 50 with t(1;19) 37, 59 CD19 expression, antigen expression during with t(4;11) 34, 57, 111 flow cytometric maturation of the with t(9;22) 57 immunophenotyping neutrophil lineage within with t(12;21) 57 3, 4, 5 the bone marrow 50 B‐lineage neoplasms, mature CD20 17–18 antigen expression during see mature B‐lineage CD21 18 maturation of the T‐ neoplasms CD22 18–19 lymphocyte lineage in the B‐lineage non‐Hodgkin CD23 19 bone marrow, thymus and lymphoma, minimal CD24 19 peripheral lymphoid residual disease CD25 19–20 tissues 52 (MRD) 78 CD26 20 37 blood grouping 27 CD27 20 ATLL see adult T‐cell B lymphocyte 49, 51, 55, 56 CD28 21 leukaemia/lymphoma BOB.1 40 CD30 21 atypical chronic myeloid BRAFV600E 40 CD31 21–22 leukaemia 35, 63 CD32 22 AUL see acute undifferentiated (auristatin) 21 CD33 22 leukaemia Burkitt lymphoma 69, 91, 111 CD34 22–23 auristatin (brentuximab CD34 expression, flow cytometric vedotin) 21 c immunophenotyping autoimmune calprotectin 40 3, 4–5 lymphoproliferative 20 CD35 23 syndrome 6, 28 camrelizumab 37 CD36 23 37 carcinoembryonic antigen see CD37 23–24 axicabtagene ciloleucel 17 CD66a‐e CD38 24 carcinoma, metastatic 95, 113 CD40 24 b case 99, 115 CD41a 24–25 B‐ALL see B‐lineage acute CAR T cell see chimaeric CD41b 25 lymphoblastic leukaemia antigen receptor T cell CD42a 25 20 Castleman disease 21 CD42b 25 basogranulin 39 CD1 12 CD42c 25 basophil 42, 49 CD2 12 CD42d 25 BCL2 39 CD3 12–13 CD43 25–26

bindex.indd 128 01-09-2020 18:39:03 Index 129

CD44 26 CD203c 36 cluster of differentiation (CD) CD45 26 CD207 36 3, 7, 11 CD45 expression, CD227 36 CMML see chronic flow cytometric CD229 36 myelomonocytic leukaemia immunophenotyping 3–4 CD235a 36 cutaneous T‐cell lymphoma CD47 26–27 CD235b 36 23, 28, 35, 37 CD49b 27 CD236 36 cyclin D1 40 CD52 27 CD236R 36–37 cytokeratin 40 CD54 27 CD241 37 CD55 27 CD246 37 d CD56 27–28 CD269 37 dabrafenib 40 CD57 28–29 CD274 37 24 CD58 29 CD279 37 20 CD59 29 CD300e 37 24, 72 CD61 29 CD303 37 DBA.44 40 CD64 29–30 CD304 37–38 desmin 40 CD65 30 CD305 38 diffuse large B‐cell CD66a‐e 30 CD319 38 lymphoma 70 CD66e see CD66a‐e CD324 38 Down’s syndrome 15, 33, 53 CD68 30 CD326 38 acute myeloid leukaemia CD68R 30 CD335 38 (AML) 28, 55 CD71 30 CD340 38 transient abnormal CD79a 31 37 myelopoiesis of Down’s CD79b 31 chimaeric antigen receptor T syndrome 15, 33, 53, 55, CD80 31 cell (CAR T cell) 12, 17, 96, 114 CD81 31 26, 34 37 CD86 31–32 chromogranin 40 CD94 32 chronic eosinophilic leukaemia e CD99 32 12, 19, 20 early T‐cell precursor acute CD103 32 chronic lymphocytic leukaemia lymphoblastic CD105 32 (CLL) 67 leukaemia 93 CD107a 32–33 case 93 early T‐cell precursor CD110 33 minimal residual disease lymphoblastic CD116 33 (MRD) 78 leukaemia 112 CD117 33 chronic lymphoproliferative E‐cadherin see CD324 CD123 33–34 disorder of NK cells 76 38 CD127 34 chronic myeloid leukaemia, EMA see eosin‐5‐maleimide CD133 34 transformation, case endoglin see CD105 CD135 34 97, 114 endothelial cell 21 CD138 34 chronic myelomonocytic enteropathy‐associated T‐cell CD157 35 leukaemia (CMML) 13, lymphoma 21, 32, 75–76 CD158a‐k 35 16, 28, 62–64, 64 eosin‐5‐maleimide (EMA) 121 CD160 35 vedotin 44 eosinophil 49 CD161 35 classical Hodgkin lymphoma eosinophil major basic CD163 35 72, 73, 95, 113 protein 40 CD180 35–36 CLL see chronic lymphocytic eosinophil peroxidase 40 CD200 36 leukaemia Ep‐CAM see CD326

bindex.indd 129 01-09-2020 18:39:03 130 Index

epithelial membrane antigen follicular T‐cell lymphoma 14 Hodgkin lymphoma see CD227 forward scatter (FSC), flow classical 72, 73, 95, 113 Erdheim–Chester disease cytometric nodular lymphocyte 40, 65 immunophenotyping predominant Hodgkin ERG 41 1–2, 3–5 lymphoma 72, 73 erythroblast 49 human T‐cell lymphotropic Ewing’s sarcoma 28, 32, 41 g virus 1 19–20 extranodal NK/T‐cell 31 lymphoma, nasal type 76 22 i genotype, immunophenotype 13 f correlation 48–55 18 FLAER see fluorescent Glanzmann’s thrombasthenia immunoglobulin 41–42 aerolysin 6, 25, 27, 29 immunohistochemistry 7–8 FLI1 41 glycophorin see CD235a; immunophenotype, genotype 34 CD235b; CD236; correlation 48–55 flow cytometric diagnosis, CD236R immunophenotype of cells of paroxysmal nocturnal glycosylphosphatidylinositol specific myeloid haemoglobinuria (GPI) 16, 78 lineages 48 78, 79 granzyme 41, 65, 75, 76 immunophenotyping of acute flow cytometric myeloid leukaemia and immunophenotyping h blastic plasmacytoid 1–7 haematogones, case dendritic cell CD19 expression 3, 4, 5 109–110, 124 neoplasm 53–54 CD34 expression 3, 4–5 haemophagocytic 18 CD45 expression 3–4 lymphohistiocytosis intestinal T‐cell lymphomas commonly used 7, 20 75–76 fluorochromes 2, 3 haemopoietic stem cell see also enteropathy‐ forward scatter (FSC) 24, 49, 122 associated T‐cell 1–2, 3–5 hairy cell leukaemia 68–69, lymphoma; monomorphic interpretation 8 93, 113 intestinal epitheliotropic limitations 8 minimal residual disease T‐cell lymphoma principles 2 (MRD) 78 intravascular large B‐cell problems and pitfalls 8 hairy cell leukaemia variant lymphoma 70 role 6–7 69, 91, 111 24 side scatter (SSC) 2, 3–5 hepatosplenic T‐cell fluorescent aerolysin lymphoma 74 k (FLAER) 41 HER2 see CD340 Ki‐67 42 paroxysmal nocturnal hereditary elliptocytosis, killer inhibitory receptor see haemoglobinuria case 119 CD158a‐k 78, 79, 122 hereditary spherocytosis, KIT see CD117 fluorochromes 1–3, 5–6, 7 case 106, 121 commonly used HHV8‐LANA1 41 l fluorochromes 2, 3 high‐grade B‐cell lymphoma Langerhans cell FMC7 41 with rearrangement of histiocytosis 65 follicular dendritic cells 12, MYC and BCL2, BCL6 or large granular lymphocytic 13, 17, 18, 19, 23, 24, 26, 35 both 70 leukaemia see T‐cell large follicular lymphoma 67–68, histiocytic sarcoma 66 granular lymphocytic 90, 111 HLA‐DR 41 leukaemia

bindex.indd 130 01-09-2020 18:39:04 Index 131

LEF1 42 chronic lymphocytic characteristic light chain‐associated leukaemia (CLL) 67 immunophenotype of amyloidosis 72 diffuse large B‐cell mature T‐cell and NK‐cell lineage and stem cell lymphoma 70 neoplasms 73, 74 markers 49 follicular lymphoma chronic lymphoproliferative 22 67–68 disorder of NK cells 76 LL (lymphoblastic hairy cell leukaemia 68–69 extranodal NK/T‐cell lymphoma) 12 hairy cell leukaemia lymphoma, nasal type 76 LMP1 42 variant 69 hepatosplenic T‐cell loncastuximab 17 high‐grade B‐cell lymphoma lymphoma 74 24 with rearrangement of intestinal T‐cell lymphomas lymphoblastic lymphoma MYC and BCL2, BCL6 or 75–76 (LL) 12 both 70 lymphomatoid papulosis 75 lymphomatoid papulosis 75 intravascular large B‐cell mycosis fungoides 75 lymphoplasmacytic lymphoma/ lymphoma 70 primary cutaneous γδ T‐cell Waldenström lymphoplasmacytic lymphoma 74–75 macroglobulinaemia 68 lymphoma/Waldenström Sézary syndrome 75 lysozyme 42 macroglobulinaemia 68 systemic EBV‐positive T‐cell mantle cell lymphoma 67 lymphoma of m marginal zone childhood 76 macrophage 50 lymphomas 68 T‐cell large granular magnification 89 persistent polyclonal B‐cell lymphocytic magrolimab 27 lymphocytosis 71 leukaemia 76 mantle cell lymphoma 67, plasmablastic lymphoma T‐cell prolymphocytic 93, 113 70–71 leukaemia 73 blastoid variant 67 primary effusion MDS (myelodysplastic marginal zone lymphomas 68 lymphoma 70 syndromes) 62–64, 65 extranodal marginal zone primary mediastinal large B‐ MDS/MPN (myelodysplastic/ lymphomas 68 cell lymphoma 70 myeloproliferative mucosa‐associated lymphoid prolymphocytic neoplasms) 62–64, 65 tissue (MALT) leukaemia 68 melanA 42 lymphoma 26 splenic diffuse red pulp small 78–79 nodal marginal zone B‐cell lymphoma 69 metamyelocyte 17, 30, 33, lymphoma 68 mature T‐lineage and NK‐ 50, 64 splenic marginal zone lineage neoplasms metastatic carcinoma 95, 113 lymphoma 68, 93, 107, 72–76 case 99, 115 113, 123 adult T‐cell leukaemia/ minimal residual disease mast cell 49 lymphoma 74 (MRD) 76–78 mast cell tryptase 42 aggressive NK‐cell acute lymphoblastic mature B‐lineage leukaemia 76 leukaemia 77–78 neoplasms 66–71 ALK‐negative anaplastic acute myeloid leukaemia Burkitt lymphoma 69 large cell lymphoma 75 (AML) 78 characteristic ALK‐positive anaplastic large antibodies used for immunophenotype of cell lymphoma 75 monitoring 77 chronic B‐cell leukaemias anaplastic large cell B‐lineage non‐Hodgkin and B‐cell lymphomas that lymphomas 75 lymphoma 78 can involve the peripheral angioimmunoblastic T‐cell chronic lymphocytic blood 66–67 lymphoma 74 leukaemia (CLL) 78

bindex.indd 131 01-09-2020 18:39:04 132 Index

minimal residual disease myeloid dendritic cell 49 18 (MRD) (cont’d) myeloperoxidase (MPO) 43 osteoclast 15, 16, 17, 21, 24 hairy cell leukaemia 78 myeloproliferative 24 multiple myeloma (plasma neoplasms 64 cell myeloma) 78 with PDGFRA p plasma cell myeloma rearrangement 92 paroxysmal nocturnal (multiple myeloma) 78 myoglobin 43 haemoglobinuria (PNH) mixed phenotype acute 78–79 leukaemia 62, 63, 93 n case 106, 121–122 MNDA 42 nasal‐type NK‐cell leukaemia/ flow cytometric diagnosis monoblast 116 lymphoma see extranodal 78, 79 monoclonal gammopathy of NK/T‐cell lymphoma, non‐haematological tumours undetermined significance nasal type 78–79 (MGUS) 20, 21, 26, 27, natural killer (NK) cell 49 PAX5 43 28, 33, 36, 38 neuroblastoma 14, 28, 31 37, 70, 76 monocyte 49 neutrophil 4, 5, 49, 50, 62, perforin 43 immature 117 64, 65 peripheral T‐cell lymphoma, mature 117 neutrophil elastase 43 not otherwise specified monomorphic intestinal NG2 43 37, 73 epitheliotropic T‐cell 37 persistent polyclonal B‐cell lymphoma 76 NK (natural killer) cell 49 lymphocytosis 71, 93, 113 mosunetuzumab 18 NK‐lineage and T‐lineage 37 18 neoplasms, mature see 18 MPO (myeloperoxidase) 43 mature T‐lineage and NK‐ plasmablastic lymphoma MRD see minimal residual lineage neoplasms 70–71 disease nodal marginal zone plasma cell 49 mucosa‐associated lymphoid lymphoma 68 plasma cell leukaemia tissue (MALT) see also marginal zone 72, 90, 111 lymphoma 26 lymphomas plasma cell myeloma (multiple see also marginal zone nodular lymphocyte myeloma) 71–72 lymphomas predominant Hodgkin minimal residual disease multiple myeloma (plasma cell lymphoma see Hodgkin (MRD) 78 myeloma) 71–72 lymphoma plasma cell neoplasms 71–72 minimal residual disease non‐haematological comparison of the typical (MRD) 78 tumours 78–79 immunophenotype of MUM1/IRF4 42 non‐Hodgkin lymphoma 13, normal plasma cells and MYC 43 18, 67, 78, 123 myeloma cells 71–72 mycosis fungoides 75 normal peripheral blood and light chain‐associated myeloblast 48, 50, 58, 59 bone marrow cells, lineage amyloidosis 72 myelocyte 15–16, 50, 64 and stem cell markers 48 multiple myeloma (plasma myelodysplastic/ NPM1 43 cell myeloma) 71–72 myeloproliferative plasma cell leukaemia 72 neoplasms (MDS/MPN) o plasma cell myeloma 62–64, 65 18 (multiple myeloma) myelodysplastic syndromes 18 71–72 (MDS) 62–64, 65 OCT‐2 43 plasmacytoid dendritic cell 49

bindex.indd 132 01-09-2020 18:39:04 Index 133

PNET (primitive Rosai–Dorfman disease 40 T‐cell large granular neuroectodermal rough endoplasmic reticulum‐ lymphocytic leukaemia tumour) 32, 41 associated antigen 44 (T‐LGLL) 76, 94, 113 PNH see paroxysmal nocturnal case 109, 124 haemoglobinuria s T‐cell prolymphocytic 31, 70 S100 44 leukaemia (T‐PLL) 72, polyclonal B lymphocytosis see Sézary syndrome (SS) 75, 94, 73, 94, 113 persistent polyclonal B‐cell 113 T‐cell receptor (TCR) αβ 44 lymphocytosis side scatter (SSC), flow T‐cell receptor (TCR) γδ 44 pre‐B cell 31, 34, 39, 41, 51 cytometric 13 pre‐pre‐B cell 51 immunophenotyping terminal deoxynucleotidyl primary cutaneous γδ T‐cell 2, 3–5 transferase (TdT) 45 lymphoma 74–75 12 therapy‐related acute myeloid primary effusion small lymphocytic lymphoma leukaemia (AML) 28, 55 lymphoma 70 (SLL) 14 thymocyte 12, 14, 19, 20, 21, 27 primary mediastinal large B‐ SOX11 44 common 13, 45, 52, 56 cell lymphoma 70 splenic diffuse red pulp small early 13, 52 primary myelofibrosis 42 B‐cell lymphoma 69 TIA‐1 45 primitive neuroectodermal splenic lymphoma with villous tisagenlecleucel 17 tumour (PNET) 32, 41 lymphocytes 34, 66 T‐LGLL see T‐cell large granular pro‐B cell 42, 43 splenic marginal zone lymphocytic leukaemia proerythroblast 22, 32, 38, 51 lymphoma 68, 93, 113 T‐lineage acute lymphoblastic programmed cell death ligand 1 see also marginal zone leukaemia (T‐ALL) see CD274 lymphomas 60–62 programmed cell death protein case 107, 123 case 103–104, 119–120 1 see CD279 SS see Sézary syndrome cortical T 12, 61 prolymphocytic leukaemia 68 subcutaneous panniculitis‐like medullary T 61 see also T‐cell prolymphocytic T‐cell lymphoma 41, 43 Pre‐T 61 leukaemia synaptophysin 44 Pro‐T 61 promonocyte 116 systemic EBV‐positive T‐cell T‐lineage and NK‐lineage promyelocyte 15, 16, 22, lymphoma of neoplasms, mature see 27, 50 childhood 76 mature T‐lineage and NK‐ prostate‐specific antigen 44 systemic mastocytosis 64–65, lineage neoplasms prostatic acid phosphatase 44 95, 113 T lymphoblastic leukaemia/ pure erythroid leukaemia 23, lymphoma (T‐ALL) 30, 36, 38, 53–54, 55 t 94, 113 tagraxofusp 34 T lymphocyte 49 r T‐ALL see T‐lineage acute 18 Reed–Sternberg cell 8, 16, 20, lymphoblastic leukaemia; TP53 45 21, 24, 73, 74, 113 T lymphoblastic T‐PLL see T‐cell prolymphocytic rhabdomyosarcoma 28, leukaemia/lymphoma leukaemia 40, 43 TAM see transient abnormal transient abnormal Richter transformation 30, myelopoiesis of Down’s myelopoiesis of Down’s 37, 119 syndrome syndrome 15, 33, 53, 55 18, 27 tartrate‐resistant acid case 96, 114 ROR1 44 phosphatase 44 38

bindex.indd 133 01-09-2020 18:39:04 134 Index

u 12 Wiskott–Aldrich syndrome 18 von Willebrand factor 24, 25, 6, 26 29, 45, 48, 54, 78 v z 22 w ZAP70 45, 67 18 Waldenström’s vemurafenib 40 macroglobulinaemia 38 venetoclax 39

bindex.indd 134 01-09-2020 18:39:04